The Autoimmune Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities

Autoimmune disorders have been one of the most prominent growth segments in the pharma industry over the last decade. A growing patient population and high levels of unmet need are the main drivers of market growth, and novel biologics are increasingly helping to fulfill patient need, with their high cost helping to drive market sales. Study findings have also shown that the early use of anti-TNF drugs can help to halt/reverse disease progression. This has further expanded patient populations and prompted the use of these drugs in early-stage treatment. ‘The Autoimmune Market Outlook to 2013’ is a report published by Business Insights that provides comprehensive coverage of major markets within the global autoimmune area, incorporating a detailed epidemiological analysis of key indications and the main factors impacting their prevalence. Current leading brands of treatment within each indication are analysed and eight of the market’s leading players are profiled. With coverage of over 95% of the total market for autoimmune products, this report reviews the factors and underlying trends that are shaping the market and identifies the most promising areas of potential growth. Forecasts for currently marketed and key pipeline products over the 2009-13 period are also provided.

Key Findings

-The global autoimmune market generated sales of $31.9bn in 2007, an increase of 14.4% over 2006 sales. The market is forecast to grow at a CAGR of 8.1% to reach a total value of $51.0bn in 2013.
-Immunosuppressant drugs dominate the automimnune market, with four products from this class accounting for 40.3% of total market sales. The highest selling immunosuppressant drug was J&J/Schering-Plough’s Remicade, with 42.1% of total sales in this class.
-Pfizer’s Celebrex dominated the COX-II market with a share of 81.3% in 2007. Celebrex maintained blockbuster status despite the earlier withdrawals of major blockbuster COX-II inhibitors such as Vioxx and Bextra.
-Roche’s Actemra is expected to be launched in the US during Q1 2010, in view of the FDA’s request for additional data and Roche’s risk mitigation strategy. Actemra is forecast to generate sales of $680m in 2013.
-Amgen is the global autoimmune market leader, having accrued a market share of 11.2% ($3.6bn) in 2007. This was driven almost entirely by Enbrel ($3.5bn) which had a sales increase of 12.2%.
-Novartis' developmental MS drug ‘fingolimod’ (FTY-720) is one of the strongest competitors to Biogen Idec's MS franchise due to its potency and convenience of once daily oral dosing.

Use this report to:

• Assess patient potential, treatment trends and sales patterns of major autoimmune indications over the period 2009-13, with this report’s coverage of osteoarthritis, rheumatoid arthritis, crohn’s disease, systemic lupus erythematosus, ulcerative colitis and multiple sclerosis markets across Japan, France, Germany, Italy, Spain, the UK and the US.
• Discover the market dynamics of the autoimmune area and understand the impact of recent events by assessing key market trends, growth drivers and the latest issues affecting product development.
• Compare the market performance and strategic positioning of major pharma companies’ autoimmune portfolios with this report’s evaluation of the franchises and market shares of Amgen, Abbott, J&J, Pfizer, Novartis, Wyeth, Roche and Astellas. • Evaluate the autoimmune pipeline compounds of leading companies with this report’s detailed analysis of clinically
• Evaluate the autoimmune pipeline compounds of leading companies with this report’s detailed analysis of clinically differentiated pipeline products by indication, and sales forecasts for key R&D pipeline products to 2013. sclerosis markets across Japan, France, Germany, Italy, Spain, the UK and the US.

Explore issues including
-Reduced commercial opportunity for Coxibs. The commercial opportunity for the COX-II inhibitor class has been substantially reduced due to cardiovascular safety concerns. The US withdrawals of Vioxx and Bextra, in addition to the non-approvals of Arcoxia and Prexige, are likely to restrict the growth prospects of this class in the near future.
-Impact of high value biologic treatments. Orencia, for use in DMARD failures, has yet to significantly affect the growth of existing agents. BMS’s Orencia and Roche’s Actemra target rheumatoid arthritis patients refractory to anti-TNFs, a population estimated to be between 20-40% of moderate/severe RA patients.
-Cost of MS treatments. Research has shown that the cost of being diagnosed with MS in the UK is nearly £17,000 per person. The research also found that among 2,000 people surveyed from across the UK, half stated that they had to leave work due to MS, which increased the potential cost to over £25,000 per person when lost employment productivity is added.
-Importance of arthritis disease management. Although several novel artrhitis treatments have been launched in recent years, it is possible for many patients to acheive effective disease control from the better use of existing medications.

Discover...

• What will be the major growth indications in the autoimmune market over 2007–13?
• Which companies were the winners and losers in this market in 2007?
• How have major launches from companies such as Amgen, Roche, Abbott and J&J performed?
• Which companies will become key players in the autoimmune market over 2007–13?
• Which products will be affected by generic competitors over the period 2007–13?
• Which pipeline products will be the growth drivers of the future?
• Which indications have the highest levels of market potential over the period 2007–13?
• What will be the competitive landscape in osteoarthritis, rheumatoid arthritis, crohn’s disease, lupus, ulcerative colitis and multiple sclerosis in 2013?

Publication: 39904
Library Code: rbhc0223
Type: Report
Format: PDF
Pages: 208